The subject invention features compounds having the structure:
##STR00001## wherein X is O, S, CH.sub.2 or NR.sub.5; Y is O or S;
R.sub.1 is H, substituted or unsubstituted C.sub.1-C.sub.15 alkyl,
C.sub.1-C.sub.8 alkylaryl, --C(O)OR.sub.4, --C(O)NR.sub.4R.sub.5,
--CR.sub.6R.sub.6'OR.sub.4, --CR.sub.6R.sub.6'OC(O)R.sub.4,
--CR.sub.6R.sub.6'OC(O)NHR.sub.7, --C(O)NR.sub.10R.sub.11,
--C(O)NR.sub.8R.sub.9NR.sub.8R.sub.9, --N(R.sub.5)C(O)NHR.sub.5, or
CH.sub.2R.sub.4; R.sub.2 is a substituted or unsubstituted, straight
chain C.sub.1--C.sub.30 alkyl or branched C.sub.3-C.sub.30 alkyl, aryl,
alkylaryl, arylalkyl, heteroarylalkyl or cycloalkyl; R.sub.3 is H or
substituted or unsubstituted C.sub.1-C.sub.6 alkyl or C.sub.3-C.sub.10
cycloalkyl; R.sub.4 is H or a substituted or unsubstituted, straight
chain or branched, C.sub.6-C.sub.30 alkyl, aryl, --CH.sub.2-aryl, aryl
--C.sub.1-C.sub.15 alkyl, heteroaryl-C.sub.1-C.sub.15alkyl or
C.sub.3-C.sub.10 cycloalkyl; R.sub.5 is H or a substituted or
unsubstituted, straight chain or branched, C.sub.6-C.sub.30 alkyl, aryl
C.sub.1-C.sub.30alkyl, heteroarylalkyl or cycloalkyl; R.sub.6 and
R.sub.6' are each independently H, substituted or unsubstituted
C.sub.1-C.sub.6 alkyl, dialkyl or C.sub.3-C.sub.10 cycloalkyl or together
form a 3-7 membered ring system; R.sub.7 is H or substituted or
unsubstituted C.sub.1-C.sub.12 alkyl or C.sub.3-C.sub.10 cycloalkyl;
R.sub.8 and R.sub.9 are each independently H, substituted or
unsubstituted C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkylaryl, or NR.sub.8R.sub.9 together form a substituted
piperazine or piperidine ring or a dihydro-1H-isoquinoline ring system,
or a specific enantiomer thereof, or a specific tautomer, or a
pharmaceutically acceptable salt thereof and a method for treating
diabetes or obesity by administering a therapeutically effective amount
of the compounds of the invention.
